Intermacs collects clinical data relevant to mechanical circulatory support devices (MCSDs) from index hospitalization through follow-up evaluations. Post implant follow-up data is collected at 1 week, 1 month, 3 months, 6 months and every 6 months thereafter. Major outcomes after implant, e.g., death, explant, rehospitalization and adverse events, are entered within 30 days of occurrence and also as part of the defined follow-up scheduled intervals.
Intermacs provides contemporary data to demonstrate outcomes, with additional insight into appropriate risk stratification and patient selection. Death, transplant, and explant are the major discrete endpoints recorded. Complex endpoints include the patient’s level of function and quality of life, critical to the evaluation of current MCSD therapy these indices are becoming increasingly important as patient survival improves, and new devices will be compared for outcomes beyond survival.
Sponsored by The National Heart, Lung and Blood Institute (NHLBI) and housed at the University of Alabama at Birmingham, Intermacs launched in June 2006 with 15 participating hospitals within the United States. The registry has quickly grown to include the majority of MCSD centers in the U.S. Intermacs is recognized as the Joint Commission mandated registry for all U.S. centers implanting MCSDs for destination therapy and now has expanded to include all interested hospitals in the United States and Canada.
Please update your Apple IOS version of Duo Security from your current version to version 3.5.1. The update is available on the Apple iTunes store (Link Below)
This update will fix the protection of the Duo Mobile Security application.
Intermacs is sensitive to site and participant confidentiality. Please use a secure e-mail to communicate confidential information with Intermacs staff. If you do not have a secure e-mail available, contact us at firstname.lastname@example.org and request access to the Intermacs secure e-mail.
This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract Number HHSN268201100025C.